4 results
The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the EMA in providing additional safety and efficacy data in approximately 150 patients with Ph+ CML whose disease had failed or who are otherwise not…
The primary objective is to assess the feasibility, safety and efficacy of Lutonix Catheter for treatment of de novo coronary artery stenosis using two distinct treatment strategies: Lutonix Catheter before or after BMS
To assess angiographic and clinical outcomes after treatment of ISR of a prior BMS in the native coronary system with the Lutonix Catheter
Primary: To compare the proportion of patients demonstrating Major Molecular Response (MMR) at 12 months (48 weeks) in the bosutinib arm with that of the imatinib arm in newly diagnosed Philadelphia chromosome positive (Ph+) chronic phase (CP)…